Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2005
03/08/2005US6864252 Treatment of cyclooxygenase mediated diseases, such as arthritis, neurodegeneration and colon cancer
03/08/2005US6864244 Polymorphism crystal structure; stability
03/08/2005US6864233 Fungicidal echinocandin derivatives and their preparation
03/08/2005US6864068 Mutant plant
03/08/2005US6864054 Polypeptides from CREB binding protein and related protein p300 for use in transcriptional regulation
03/08/2005US6863893 Vaccination of mammals with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of an antibody that protects vaccine recipient from infection
03/08/2005US6863647 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
03/08/2005CA2349672C Method for preparing capsules consisting of a liquid active material core enclosed in a mineral coating
03/08/2005CA2120743C Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives
03/03/2005WO2005019250A1 Staphylococcus antibiotic peptides with a broad spectrum of action
03/03/2005WO2005019246A1 Coronavirus vaccines, therapeutics and diagnostics
03/03/2005WO2005019245A1 Heptadepsin
03/03/2005WO2005019238A1 Novel azalide and azalactam derivatives and process for the production of the same
03/03/2005WO2005019237A1 Novel sulfenamides
03/03/2005WO2005019236A1 Novel sulfenamide oxides
03/03/2005WO2005019217A1 Crystal of 1-methyl carbapenem compound
03/03/2005WO2005019214A1 Novel antimicrobial aryloxazolidinone compounds
03/03/2005WO2005019213A1 N-aryl-2-cyanooxazolidinones and their derivatives
03/03/2005WO2005019196A1 3-aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them
03/03/2005WO2005019186A1 2-aminobenzimidazole derivatives for use in the treatment of hiv/aids
03/03/2005WO2005018743A1 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
03/03/2005WO2005018701A1 Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
03/03/2005WO2005018655A1 Use of noni in relation to oral pathologies, for example, in order to combat problems associated with asialia and hyposialia
03/03/2005WO2005018641A2 Novel use of quinolone antibiotics
03/03/2005WO2005018556A2 Hydroxylamine substituted imidazo-containing compounds
03/03/2005WO2005018551A2 Oxime substituted imidazo-containing compounds
03/03/2005WO2005018531A2 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
03/03/2005WO2005007070A3 Stable pharmaceutical composition
03/03/2005WO2005003147A3 Modified fluorinated nucleoside analogues
03/03/2005WO2004110481A3 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
03/03/2005WO2004106345A3 Heteroaryl-ethanolamine derivatives as antiviral agents
03/03/2005WO2004025256A3 Viral deconstruction through capsid assembly in vitro
03/03/2005WO2004001058A3 Transcription factor modulating compounds and methods of use thereof
03/03/2005WO2003048349A3 Acetoacetyl-coa thiolase and use of for the identification of novel fungicidal substances
03/03/2005WO2003045317A3 Therapeutic protein and treatments
03/03/2005US20050050580 Transgenic animal expressing hla-a24 and utilization thereof
03/03/2005US20050050191 Storage network and method for storage network device mapping
03/03/2005US20050049408 That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits
03/03/2005US20050049310 Aryl and heteroaryl compounds, compositions and methods of use
03/03/2005US20050049292 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression
03/03/2005US20050049263 Purine analogs having hsp90-inhibiting activity
03/03/2005US20050049260 2-phenyl-4-pyridinyl- or -pyrimidinyl derivatives, e.g., N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-pyrazolo[1,5-a]pyridin-7-amine and; especially for treatment of herpes simplex virus 1 and 2
03/03/2005US20050049259 Viricides; for the prophylaxis and treatment of herpes viral infections
03/03/2005US20050049258 Enzyme inhibitors for phosphodiesterase isozymes for treatment of asthma, chronic bronchitis and chronic obstructive pulmonary disease
03/03/2005US20050049251 Inhibitors of p38
03/03/2005US20050049245 Herpes viruses; such as N-(4-chlorobenzyl)-2-(((2-(2-furyl)-2-hydroxyethyl)(methyl)amino) methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide
03/03/2005US20050049234 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents
03/03/2005US20050049233 Transdermal administering of testosterone
03/03/2005US20050049216 Immunostimulatory nucleic acid molecules
03/03/2005US20050049215 contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulating interferon-alpha to treat viral infections; oligonucleotide linked to a biodegradable delivery complex
03/03/2005US20050049205 Product from rose hips e.g. 3- beta -D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (GOPO); arthritis and osteoarthritis
03/03/2005US20050049202 For treating disorders associated with excessive cytokine release such as interleukin-1 (IL-1) for example infection, cancer, asthma, coronary restenosis, autoimmune disease, cirrhosis, entotoxemia, reperfusion injury and septic shock; lactone or lactam-benzoates or benzamides
03/03/2005US20050049198 Contacting a cardiac ryanodine receptor (RyR2) with a fragment of a dihydropyridine receptor (DHPR) polypeptide; ischemic heart disease, congestive heart failure, cardiac hypertrophy (calcium overload), dysrhythmia, or heart attack, cardiomyopathy
03/03/2005US20050049182 Therapeutic formulation comprising cationic peptide, viscosity-increasing agent, and solvent, wherein the cationic peptide contains up to 35 amino acids; use in treating or preventing infectious disease associated with foreign bodies, primary or seconary infection sites
03/03/2005US20050049181 Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
03/03/2005US20050048645 Dendritic cells which present cryptococcus antigens for use in generating vaccines to prevent or treat microorganismal infection; immunotherapy; drug targeting and parasitic infection
03/03/2005US20050048590 Streptococcal enolase for use in generating immunoglobulins for use in prevention and treatment of microorganismal infection; immunotherapy
03/03/2005US20050048557 Expression vector comprising nucleotide sequences coding microorganismsal protein for use in developing vaccine agents which prevent bacterial infection; bactericides; microbiocides
03/03/2005US20050048478 Preparing agents which prevent and/or treat viral diseases; immunotherapy; mimetics
03/03/2005US20050048471 Albumin derivatives with therapeutic functions
03/03/2005US20050048469 Novel human parvovirus B19 receptor and uses thereof
03/03/2005US20050048134 Therapy, prevention of papillomavirus infections; antiinflammatory agents; wound healing agents
03/03/2005US20050048114 Antibiotic product, use and formulation thereof
03/03/2005US20050048104 Transdermal drug delivery devices comprising a polyurethane drug reservoir
03/03/2005US20050048098 Semirigid eye implant; glycolic acid-lactic acid copolymer and release moderator for dexamethasome;
03/03/2005US20050048081 Immunogenic compositions comprising DAL/DAT double mutant, auxotrophic attenuated strains of listeria and their mehods of use
03/03/2005US20050048079 Induction response in cells; joining to adenosine triphosphate binding domain; therapy for Aids; anticancer agents
03/03/2005US20050048076 Mutant endotoxin for use in prevention of bacterial infections; bactericides; microbiocides
03/03/2005US20050048062 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
03/03/2005US20050048055 Use of CD40 engagement to alter T cell receptor usage
03/03/2005US20050048052 Bioassay for detecting expression of mammalian CC-chemokine receptor 2, by binding of antibody or antigen-binding fragment; human or humanized monoclonal antibody; test kits
03/03/2005US20050048029 Nucleotide sequence for diagnosis, prevention, therapy of cancer, inflammation, autoimmune disease and infections
03/03/2005DE10335634A1 Antimikrobielle Wirkstoffe Antimicrobial Agents
03/03/2005CA2644316A1 Crystal of 1-methyl carbapenem compound
03/03/2005CA2536480A1 Novel antimicrobial aryloxazolidinone compounds
03/03/2005CA2535951A1 Bacterial strains, compositions including same and probiotic use thereof
03/03/2005CA2535802A1 Novel sulfenamides
03/03/2005CA2535800A1 Novel sulfenamide oxides
03/03/2005CA2535796A1 N-aryl-2-cyanooxazolidinones and their derivatives
03/03/2005CA2535745A1 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
03/03/2005CA2535120A1 Hydroxylamine substituted imidazo-containing compounds
03/03/2005CA2535117A1 Oxime substituted imidazo-containing compounds
03/03/2005CA2533396A1 3-aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them
03/03/2005CA2526431A1 Compositions and methods for treatment of severe acute respiratory syndrome (sars)
03/03/2005CA2523658A1 Rnai agents for anti-sars coronavirus therapy
03/02/2005EP1510580A2 Novel hepatitis C E1 and E2 truncated polypeptides and methods of obtaining the same
03/02/2005EP1510518A2 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels
03/02/2005EP1510511A1 Gingerol analogues and use thereof
03/02/2005EP1510214A2 8a-azalides as veterinary antimicrobial agents
03/02/2005EP1509621A1 Treatment with cytokines for alzheimer's disease
03/02/2005EP1509543A2 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus
03/02/2005EP1509541A2 Novel recombinant anticoagulant proteins
03/02/2005EP1509538A1 6,11 bicyclic erythromycin derivatives
03/02/2005EP1509537A2 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
03/02/2005EP1509529A2 Esters in position 20 of camptothecins
03/02/2005EP1509526A2 Imidazo(1,2-a)pyrazin-8-ylamines, method of making, and method of use thereof
03/02/2005EP1509519A1 Crystalline fluoroquinolone arginine salt form
03/02/2005EP1509516A1 Inhibitors of the gpib -vwf interaction, their preparation and use
03/02/2005EP1509506A1 Pyridazine derivatives
03/02/2005EP1509489A1 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
1 ... 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 ... 1798